Overview

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
University of Aarhus
Treatments:
Amiloride
Arginine Vasopressin
Calcitonin
Calcitonin Gene-Related Peptide
Hydrochlorothiazide
Indomethacin
Katacalcin
Salmon calcitonin
Sildenafil Citrate